The Board of Directors appointed Thomas Freeburg as Chief Financial Officer, effective September 1, 2026. Mr. Freeburg will receive a base salary of $250,000, an annual bonus up to 50% of base, and 50,000 stock options with an exercise price of $8.83 per share. The appointment is for a two-year term at the Board's discretion. Niki BioSolutions operates in the biotechnology sector.
